Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
Abstract Chimeric antigen receptor-modified T cells (CAR-T cells) have shown good effects in the treatment of hematologic cancers; however, they may cause on-target off-tumor toxicity because of minimal expression of tumor-associated antigens (TAAs) on normal tissues, particularly in the context of...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40364-020-00238-9 |